Search: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)

Abstract: 917
Congress: ESMO 2012
Type: Late-Breaking Abstract
Topic: Gastrointestinal tumors, non-colorectal
Authors: A.X. Zhu1, O. Rosmorduc2, J. Evans3, P. Ross4, A. Santoro5, F.J. Carrilho6, M.-A. Leberre7, M. Jensen8, G. Meinhardt9, Y.-K. Kang10; 1Boston, MA/US, 2Paris/FR, 3Glasgow/UK, 4London/UK, 5Rozzano/IT, 6Sao Paulo/BR, 7Loos/FR, 8Leverkusen/DE, 9Montville, NJ/US, 10Seoul/KR